Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
MTC
bispecific antibody
carcinoembryonic antigen
immuno-PET
pretargeted radioimmunoimaging
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
08
07
2020
accepted:
13
01
2021
pubmed:
7
2
2021
medline:
7
1
2022
entrez:
6
2
2021
Statut:
ppublish
Résumé
Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the
Identifiants
pubmed: 33547213
pii: jnumed.120.252791
doi: 10.2967/jnumed.120.252791
pmc: PMC8882894
doi:
Substances chimiques
CEACAM5 protein, human
0
Carcinoembryonic Antigen
0
GPI-Linked Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221-1227Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Nucl Med. 1993 Aug;34(8):1267-73
pubmed: 8326383
Acad Radiol. 2012 Oct;19(10):1290-9
pubmed: 22819076
J Nucl Med. 1998 Jul;39(7):1172-8
pubmed: 9669389
J Clin Oncol. 2017 Oct 10;35(29):3338-3346
pubmed: 28817371
J Clin Endocrinol Metab. 2005 Nov;90(11):6077-84
pubmed: 16091497
Cancer. 2006 Nov 1;107(9):2134-42
pubmed: 17019736
Front Med (Lausanne). 2015 Nov 27;2:84
pubmed: 26640780
J Nucl Med. 2009 Jun;50(6):991-8
pubmed: 19443594
Int J Mol Sci. 2016 Dec 28;18(1):
pubmed: 28036044
J Nucl Med. 2020 Aug;61(8):1205-1211
pubmed: 32169921
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Nucl Med. 2012 Dec;53(12):1863-71
pubmed: 23081996
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2004-2013
pubmed: 28646462
J Nucl Med. 2012 Aug;53(8):1185-92
pubmed: 22743249
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1593-602
pubmed: 24643780
J Clin Oncol. 2006 Apr 10;24(11):1705-11
pubmed: 16549819
Mol Cancer Ther. 2010 Apr;9(4):1019-27
pubmed: 20354120
J Clin Endocrinol Metab. 1984 May;58(5):889-94
pubmed: 6707192
Oncologist. 2013;18(10):1093-100
pubmed: 24037980
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7
pubmed: 17878252
J Thyroid Res. 2019 Jul 7;2019:1893047
pubmed: 31360432
Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6
pubmed: 16636283
Front Pharmacol. 2015 Mar 31;6:54
pubmed: 25873896
J Nucl Med. 2016 Oct;57(10):1505-1511
pubmed: 27230928
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):61-77
pubmed: 31482429
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):335-347
pubmed: 28911729
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3250-3259
pubmed: 29846642
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
J Nucl Med. 2011 Dec;52(12):1855-63
pubmed: 22052128
Clin Nucl Med. 2020 May;45(5):341-348
pubmed: 32049723
Int J Mol Imaging. 2012;2012:324686
pubmed: 22852077
Cancer Med. 2017 Apr;6(4):798-808
pubmed: 28211613
Thyroid. 2010 May;20(5):527-33
pubmed: 20450432